Aller au contenu principal

Publications

Please find here all the publications in which the Quebec Parkinson Network and its members are involved.

2021

  • Combined 5-HT2A and mGlu2 modulation for the treatment of dyskinesia and psychosis in Parkinson’s disease. Neuropharmacology. Kwan C, Frouni I, Nuara SG, Belliveau S, Kang W, Hamadjida A, Bedard D, Beaudry F, Panisset M, Gourdon JC, Huot P.  2021;186:108465.
  • Pharmacological Inhibition of Brain EGFR Activation By a BBB-penetrating Inhibitor, AZD3759, Attenuates alpha-synuclein Pathology in a Mouse Model of alpha-Synuclein Propagation. Tavassoly O, Del Cid Pellitero E, Larroquette F, Cai E, Thomas RA, Soubannier V, Luo W, Durcan TM, Fon EA.  Neurotherapeutics. 2021.
  • Anti-Apoptotic and Anti-Inflammatory Role of Trans epsilon-Viniferin in a Neuron-Glia Co-Culture Cellular Model of Parkinson’s Disease. Sergi D, Gelinas A, Beaulieu J, Renaud J, Tardif-Pellerin E, Guillard J, Martinoli MG. Foods. 2021;10(3).
  • Is LRRK2 the missing link between inflammatory bowel disease and Parkinson’s disease? Herrick MK, Tansey MG. NPJ Parkinsons Dis. 2021;7(1):26.
  • Novel Associations of BST1 and LAMP3 With REM Sleep Behavior Disorder. Mufti K, Yu E, Rudakou U, Krohn L, Ruskey JA, Asayesh F, Laurent SB, Spiegelman D, Arnulf I, Hu MTM, Montplaisir JY, Gagnon JF, Desautels A, Dauvilliers Y, Gigli GL, Valente M, Janes F, Bernardini A, Hogl B, Stefani A, Holzknecht E, Sonka K, Kemlink D, Oertel W, Janzen A, Plazzi G, Antelmi E, Figorilli M, Puligheddu M, Mollenhauer B, Trenkwalder C, Sixel-Doring F, Cochen De Cock V, Monaca CC, Heidbreder A, Ferini-Strambi L, Dijkstra F, Viaene M, Abril B, Boeve BF, Trempe JF, Rouleau GA, Postuma RB, Gan-Or Z. Neurology. 2021;96(10):e1402-e12.
  • Weeding through the haze: a survey on cannabis use among people living with Parkinson’s disease in the US. Feeney MP, Bega D, Kluger BM, Stoessl AJ, Evers CM, De Leon R, Beck JC. NPJ Parkinsons Dis. 2021;7(1):21.
  • Growth differentiation factor 5 exerts neuroprotection in an alpha-synuclein rat model of Parkinson’s disease. Goulding SR, Concannon RM, Morales-Prieto N, Villalobos-Manriquez F, Clarke G, Collins LM, Levesque M, Wyatt SL, Sullivan AM, O’Keeffe GW. Brain. 2021;144(2):e14.
  • Targeted sequencing of Parkinson’s disease loci genes highlights SYT11, FGF20 and other associations. Rudakou U, Yu E, Krohn L, Ruskey JA, Asayesh F, Dauvilliers Y, Spiegelman D, Greenbaum L, Fahn S, Waters CH, Dupre N, Rouleau GA, Hassin-Baer S, Fon EA, Alcalay RN, Gan-Or Z. Brain. 2021;144(2):462-72.
  • Probable REM sleep behavior disorder is associated with longitudinal cortical thinning in Parkinson’s disease. Yoon EJ, Monchi O. NPJ Parkinsons Dis. 2021;7(1):19.
  • Investigating the relationship between the SNCA gene and cognitive abilities in idiopathic Parkinson’s disease using machine learning. Ramezani M, Mouches P, Yoon E, Rajashekar D, Ruskey JA, Leveille E, Martens K, Kibreab M, Hammer T, Kathol I, Maarouf N, Sarna J, Martino D, Pfeffer G, Gan-Or Z, Forkert ND, Monchi O. Sci Rep. 2021;11(1):4917.
  • Action fluency identifies different sex, age, global cognition, executive function and brain activation profile in non-demented patients with Parkinson’s disease. Auclair-Ouellet N, Hanganu A, Mazerolle EL, Lang ST, Kibreab M, Ramezani M, Haffenden A, Hammer T, Cheetham J, Kathol I, Pike GB, Sarna J, Martino D, Monchi O. J Neurol. 2021;268(3):1036-49.
  • Neuroprotective benefits of grape seed and skin extract in a mouse model of Parkinson’s disease. Ben Youssef S, Brisson G, Doucet-Beaupre H, Castonguay AM, Gora C, Amri M, Levesque M. Nutr Neurosci. 2021;24(3):197-211.
  • Mitochondrial and Clearance Impairment in p.D620N VPS35 Patient-Derived Neurons. Hanss Z, Larsen SB, Antony P, Mencke P, Massart F, Jarazo J, Schwamborn JC, Barbuti PA, Mellick GD, Kruger R. Mov Disord. 2021;36(3):704-15.
  • Vascular Contributions to Neurodegeneration: Protocol of the COMPASS-ND Study. Smith EE, Duchesne S, Gao F, Saad F, Whitehead V, McCreary CR, Frayne R, Gauthier S, Camicioli R, Borrie M, Black SE. Can J Neurol Sci. 2021:1-8.
  • Current and future applications of induced pluripotent stem cell-based models to study pathological proteins in neurodegenerative disorders. de Rus Jacquet A, Denis HL, Cicchetti F, Alpaugh M. Mol Psychiatry. 2021.
  • Multimodal phenotypic axes of Parkinson’s disease. Markello RD, Shafiei G, Tremblay C, Postuma RB, Dagher A, Misic B. NPJ Parkinsons Dis. 2021;7(1):6.
  • Olfactory-Trigeminal Interactions in Patients with Parkinson’s Disease. Tremblay C, Frasnelli J. Chem Senses. 2021;46.
  • International Parkinson Disease Genomics C. Analysis of DNM3 and VAMP4 as genetic modifiers of LRRK2 Parkinson’s disease. Brown EE, Blauwendraat C, Trinh J, Rizig M, Nalls MA, Leveille E, Ruskey JA, Jonvik H, Tan MMX, Bandres-Ciga S, Hassin-Baer S, Brockmann K, Infante J, Tolosa E, Ezquerra M, Ben Romdhan S, Benmahdjoub M, Arezki M, Mhiri C, Hardy J, Singleton AB, Alcalay RN, Gasser T, Grosset DG, Williams NM, Pittman A, Gan-Or Z, Fernandez-Santiago R, Brice A, Lesage S, Farrer M, Wood N, Morris HR. Neurobiol Aging. 2021;97:148 e17- e24.
  • Analysis of Heterozygous PRKN Variants and Copy-Number Variations in Parkinson’s Disease. Yu E, Rudakou U, Krohn L, Mufti K, Ruskey JA, Asayesh F, Estiar MA, Spiegelman D, Surface M, Fahn S, Waters CH, Greenbaum L, Espay AJ, Dauvilliers Y, Dupre N, Rouleau GA, Hassin-Baer S, Fon EA, Alcalay RN, Gan-Or Z. Mov Disord. 2021;36(1):178-87.
  • Effect of the mGlu2 positive allosteric modulator CBiPES on dyskinesia, psychosis-like behaviours and parkinsonism in the MPTP-lesioned marmoset. Frouni I, Kwan C, Nuara SG, Belliveau S, Kang W, Hamadjida A, Bedard D, Gourdon JC, Huot P. J Neural Transm (Vienna). 2021;128(1):73-81.
  • Selective blockade of the 5-HT3 receptor acutely alleviates dyskinesia and psychosis in the parkinsonian marmoset. Kwan C, Nuara SG, Bedard D, Gaudette F, Gourdon JC, Beaudry F, Huot P. Neuropharmacology. 2021;182:108386.
  • Comprehensive Analysis of Familial Parkinsonism Genes in Rapid-Eye-Movement Sleep Behavior Disorder. Mufti K, Rudakou U, Yu E, Krohn L, Ruskey JA, Asayesh F, Laurent SB, Spiegelman D, Arnulf I, Hu MTM, Montplaisir JY, Gagnon JF, Desautels A, Dauvilliers Y, Gigli GL, Valente M, Janes F, Hogl B, Stefani A, Holzknecht E, Sonka K, Kemlink D, Oertel W, Janzen A, Plazzi G, Antelmi E, Figorilli M, Puligheddu M, Mollenhauer B, Trenkwalder C, Sixel-Doring F, Cochen De Cock V, Monaca CC, Heidbreder A, Ferini-Strambi L, Dijkstra F, Viaene M, Abril B, Boeve BF, Postuma RB, Rouleau GA, Gan-Or Z. Mov Disord. 2021;36(1):235-40.
  • Genetic and Environmental Factors in Parkinson’s Disease Converge on Immune Function and Inflammation. Kline EM, Houser MC, Herrick MK, Seibler P, Klein C, West A, Tansey MG. Mov Disord. 2021;36(1):25-36.
  • Striatal Dopamine Deficit and Motor Impairment in Idiopathic Normal Pressure Hydrocephalus. Pozzi NG, Brumberg J, Todisco M, Minafra B, Zangaglia R, Bossert I, Trifiro G, Ceravolo R, Vitali P, Isaias IU, Fasano A, Pacchetti C. Mov Disord. 2021;36(1):124-32.
  • World Brain Day 2020: Join Us to “Move to End Parkinson’s Disease”: A World Federation of Neurology and International Parkinson and Movement Disorders Society Collaboration. Wijeratne T, Fox S. Can J Neurol Sci. 2021;48(1):56-8.
  • Development of an alpha-synuclein knockdown peptide and evaluation of its efficacy in Parkinson’s disease models. Jin JW, Fan X, Del Cid-Pellitero E, Liu XX, Zhou L, Dai C, Gibbs E, He W, Li H, Wu X, Hill A, Leavitt BR, Cashman N, Liu L, Lu J, Durcan TM, Dong Z, Fon EA, Wang YT. Commun Biol. 2021;4(1):232.
  • Relationships of gut microbiota, short-chain fatty acids, inflammation, and the gut barrier in Parkinson’s disease. Aho VTE, Houser MC, Pereira PAB, Chang J, Rudi K, Paulin L, Hertzberg V, Auvinen P, Tansey MG, Scheperjans F. Mol Neurodegener. 2021;16(1):6.
  • The Role of DJ-1 in Cellular Metabolism and Pathophysiological Implications for Parkinson’s Disease. Mencke P, Boussaad I, Romano CD, Kitami T, Linster CL, Kruger R. Cells. 2021;10(2).
  • Granisetron, a selective 5-HT3 antagonist, reduces L-3,4-dihydroxyphenylalanine-induced abnormal involuntary movements in the 6-hydroxydopamine-lesioned rat. Kwan C, Frouni I, Bedard D, Hamadjida A, Huot P. Behav Pharmacol. 2021;32(1):43-53.
  • The Spectrum of Sleep Disorders in Parkinson Disease: A Review. Lajoie AC, Lafontaine AL, Kaminska M. Chest. 2021;159(2):818-27.
  • The effects of exercise on sleep quality in persons with Parkinson’s disease: A systematic review with meta-analysis. Cristini J, Weiss M, De Las Heras B, Medina-Rincon A, Dagher A, Postuma RB, Huber R, Doyon J, Rosa-Neto P, Carrier J, Amara AW, Roig M. Sleep Med Rev. 2021;55:101384.
  • A Prodromal Brain-Clinical Pattern of Cognition in Synucleinopathies. Rahayel S, Postuma RB, Montplaisir J, Misic B, Tremblay C, Vo A, Lewis S, Matar E, Ehgoetz Martens K, Blanc F, Yao C, Carrier J, Monchi O, Gaubert M, Dagher A, Gagnon JF. Ann Neurol. 2021;89(2):341-57.
  • Serotonergic System Impacts Levodopa Response in Early Parkinson’s and Future Risk of Dyskinesia. Fu JF, Matarazzo M, McKenzie J, Neilson N, Vafai N, Dinelle K, Felicio AC, McKeown MJ, Stoessl AJ, Sossi V. Mov Disord. 2021;36(2):389-97.
  • Patterns and predictors of referrals to allied health services for individuals with Parkinson’s disease: A Parkinson’s foundation (PF) QII study. Roberts AC, Rafferty MR, Wu SS, Miao G, Cubillos F, Simuni T, Parkinson’s Foundation Quality Improvement Initiative Investigators Steering Committee M, Investigators PQP. Parkinsonism Relat Disord. 2021;83:115-22.
  • Parkinson’s Disease Subtypes: Critical Appraisal and Recommendations. Mestre TA, Fereshtehnejad SM, Berg D, Bohnen NI, Dujardin K, Erro R, Espay AJ, Halliday G, van Hilten JJ, Hu MT, Jeon B, Klein C, Leentjens AFG, Marinus J, Mollenhauer B, Postuma R, Rajalingam R, Rodriguez-Violante M, Simuni T, Surmeier DJ, Weintraub D, McDermott MP, Lawton M, Marras C. J Parkinsons Dis. 2021;11(2):395-404.
  • Patterns of brain activity during a set-shifting task linked to mild behavioral impairment in Parkinson’s disease. Jin Yoon E, Ismail Z, Kathol I, Kibreab M, Hammer T, Lang S, Ramezani M, Auclair-Ouellet N, Sarna JR, Martino D, Furtado S, Monchi O. Neuroimage Clin. 2021;30:102590.
  • Editorial: Celebrating the Diversity of Genetic Research to Dissect the Pathogenesis of Parkinson’s Disease. Farrer MJ, Bardien S, Hattori N, Lesage S, Ross OA, Mellick GD, Kruger R. Front Neurol. 2021;12:648417.
  • No Evidence for a Causal Relationship Between Cancers and Parkinson’s Disease. Senkevich K, Bandres-Ciga S, Yu E, Liyanage UE, International Parkinson Disease Genomics C, Noyce AJ, Gan-Or Z. J Parkinsons Dis. 2021;11(2):801-9.
  • Machine Learning for the Diagnosis of Parkinson’s Disease: A Review of Literature. Mei J, Desrosiers C, Frasnelli J. Front Aging Neurosci. 2021;13:633752.
  • Treating Parkinson’s Disease with Antibodies: Previous Studies and Future Directions. Castonguay AM, Gravel C, Levesque M. J Parkinsons Dis. 2021;11(1):71-92.
  • Clinical and Genetic Analysis of Costa Rican Patients With Parkinson’s Disease. Torrealba-Acosta G, Yu E, Lobo-Prada T, Ruiz-Martinez J, Gorostidi-Pagola A, Gan-Or Z, Carazo-Cespedes K, Trempe JF, Mata IF, Fornaguera-Trias J. Front Neurol. 2021;12:656342.

2020

  • Transgenic Mice Expressing Human alpha-Synuclein in Noradrenergic Neurons Develop Locus Ceruleus Pathology and Nonmotor Features of Parkinson’s Disease. Butkovich LM, Houser MC, Chalermpalanupap T, Porter-Stransky KA, Iannitelli AF, Boles JS, Lloyd GM, Coomes AS, Eidson LN, De Sousa Rodrigues ME, Oliver DL, Kelly SD, Chang J, Bengoa-Vergniory N, Wade-Martins R, Giasson BI, Joers V, Weinshenker D, Tansey MG. J Neurosci. 2020;40(39):7559-76.
  • Using High-Content Screening to Generate Single-Cell Gene-Corrected Patient-Derived iPS Clones Reveals Excess Alpha-Synuclein with Familial Parkinson’s Disease Point Mutation A30P. Barbuti P, Antony P, Santos B, Massart F, Cruciani G, Dording C, Arias J, Schwamborn J, Kruger R. Cells. 2020;9(9).
  • A patient-based model of RNA mis-splicing uncovers treatment targets in Parkinson’s disease. Boussaad I, Obermaier CD, Hanss Z, Bobbili DR, Bolognin S, Glaab E, Wolynska K, Weisschuh N, De Conti L, May C, Giesert F, Grossmann D, Lambert A, Kirchen S, Biryukov M, Burbulla LF, Massart F, Bohler J, Cruciani G, Schmid B, Kurz-Drexler A, May P, Duga S, Klein C, Schwamborn JC, Marcus K, Woitalla D, Vogt Weisenhorn DM, Wurst W, Baralle M, Krainc D, Gasser T, Wissinger B, Kruger R. Sci Transl Med. 2020;12(560).
  • Lack of evidence for genetic association of saposins A, B, C and D with Parkinson’s disease. Sosero YL, Bandres-Ciga S, Hassin-Baer S, Alcalay RN, Gan-Or Z, International Parkinson’s Disease Genomics C. Brain. 2020;143(9):e72.
  • Parkinson’s disease progression in the substantia nigra: location, location, location. Vaillancourt DE, Mitchell T. Brain. 2020;143(9):2628-30.
  • Emerging concepts for precision medicine in Parkinson’s disease with focus on genetics. Stute L, Kruger R. Fortschr Neurol Psychiatr. 2020;88(9):558-66.
  • Lumboperitoneal shunt in idiopathic normal pressure hydrocephalus: a prospective controlled study. Todisco M, Picascia M, Pisano P, Zangaglia R, Minafra B, Vitali P, Rognone E, Pichiecchio A, Ceravolo R, Vanacore N, Fasano A, Pacchetti C. J Neurol. 2020;267(9):2556-66.
  • The role of inhibitors of COMT and MAO-B in the therapy of Parkinson’s disease. FWoitalla D, Kruger R, Lorenzl S, Muller T, Oelwein G, Storch A, Wolz M, Wullner U. ortschr Neurol Psychiatr. 2020;88(9):620-33.
  • Nonlinear pharmacodynamics of levodopa through Parkinson’s disease progression. Veronneau-Veilleux F, Ursino M, Robaey P, Levesque D, Nekka F. Chaos. 2020;30(9):093146.
  • A new approach toward gait training in patients with Parkinson’s Disease. Carvalho LP, Mate KKV, Cinar E, Abou-Sharkh A, Lafontaine AL, Mayo NE. Gait Posture. 2020;81:14-20.
  • The history of Freezing-of-gait in Parkinson’s disease – from phenomena to symptom. Klucken J, Winkler J, Kruger R, Jost W. Fortschr Neurol Psychiatr. 2020;88(9):573-81.
  • Excess of singleton loss-of-function variants in Parkinson’s disease contributes to genetic risk. Bobbili DR, Banda P, Kruger R, May P. J Med Genet. 2020;57(9):617-23.
  • Common and unique connectivity at the interface of motor, neuropsychiatric, and cognitive symptoms in Parkinson’s disease: A commonality analysis. Lang S, Ismail Z, Kibreab M, Kathol I, Sarna J, Monchi O. Hum Brain Mapp. 2020;41(13):3749-64.
  • Variants in the Niemann-Pick type C gene NPC1 are not associated with Parkinson’s disease. Ouled Amar Bencheikh B, Senkevich K, Rudakou U, Yu E, Mufti K, Ruskey JA, Asayesh F, Laurent SB, Spiegelman D, Fahn S, Waters C, Monchi O, Dauvilliers Y, Espay AJ, Dupre N, Greenbaum L, Hassin-Baer S, Rouleau GA, Alcalay RN, Fon EA, Gan-Or Z. Neurobiol Aging. 2020;93:143 e1- e4.
  • COVID-19 and selective vulnerability to Parkinson’s disease. Pavel A, Murray DK, Stoessl AJ. Lancet Neurol. 2020;19(9):719.
  • SMPD1 variants do not have a major role in rapid eye movement sleep behavior disorder. Rudakou U, Futhey NC, Krohn L, Ruskey JA, Heilbron K, Cannon P, andMe Research T, Alam A, Arnulf I, Hu MTM, Montplaisir JY, Gagnon JF, Desautels A, Dauvilliers Y, Toffoli M, Gigli GL, Valente M, Hogl B, Stefani A, Holzknecht E, Sonka K, Kemlink D, Oertel W, Janzen A, Plazzi G, Antelmi E, Figorilli M, Puligheddu M, Mollenhauer B, Trenkwalder C, Sixel-Doring F, De Cock VC, Monaca CC, Heidbreder A, Ferini-Strambi L, Dijkstra F, Viaene M, Abril B, Boeve BF, Postuma RB, Rouleau GA, Gan-Or Z. Neurobiol Aging. 2020;93:142 e5- e7.
  • VGluT2 Expression in Dopamine Neurons Contributes to Postlesional Striatal Reinnervation. Kouwenhoven WM, Fortin G, Penttinen AM, Florence C, Delignat-Lavaud B, Bourque MJ, Trimbuch T, Luppi MP, Salvail-Lacoste A, Legault P, Poulin JF, Rosenmund C, Awatramani R, Trudeau LE. J Neurosci. 2020;40(43):8262-75.
  • Precision medicine in Parkinson’s disease patients with LRRK2 and GBA risk variants – Let’s get even more personal. von Linstow CU, Gan-Or Z, Brundin P. Transl Neurodegener. 2020;9(1):39.
  • Characterization of a Cul9-Parkin double knockout mouse model for Parkinson’s disease. Hollville E, Joers V, Nakamura A, Swahari V, Tansey MG, Moy SS, Deshmukh M. Sci Rep. 2020;10(1):16886.
  • Body-first versus brain-first biological subtyping of Parkinson’s disease. Bohnen NI, Postuma RB. Brain. 2020;143(10):2871-3.
  • Sex effects on brain structure in de novo Parkinson’s disease: a multimodal neuroimaging study. Tremblay C, Abbasi N, Zeighami Y, Yau Y, Dadar M, Rahayel S, Dagher A. Brain. 2020;143(10):3052-66.
  • Longitudinal Measurements of Glucocerebrosidase activity in Parkinson’s patients. Alcalay RN, Wolf P, Chiang MSR, Helesicova K, Zhang XK, Merchant K, Hutten SJ, Scherzer C, Caspell-Garcia C, Blauwendraat C, Foroud T, Nudelman K, Gan-Or Z, Simuni T, Chahine LM, Levy O, Zheng D, Li G, Sardi SP, Parkinson’s Progression Markers I. Ann Clin Transl Neurol. 2020;7(10):1816-30.
  • Generation of two iPS cell lines (HIHDNDi001-A and HIHDNDi001-B) from a Parkinson’s disease patient carrying the heterozygous p.A30P mutation in SNCA. Barbuti PA, Santos BFR, Dording CM, Cruciani G, Massart F, Hummel A, Kruger R. Stem Cell Res. 2020;48:101951.
  • The MPTP-lesioned marmoset model of Parkinson’s disease: proposed efficacy thresholds that may potentially predict successful clinical trial results. Beaudry F, Huot P. J Neural Transm (Vienna). 2020;127(10):1343-58.
  • Non-Dopaminergic Treatments for Motor Control in Parkinson’s Disease: An Update. Gonzalez-Latapi P, Bhowmick SS, Saranza G, Fox SH. CNS Drugs. 2020;34(10):1025-44.
  • Rare and novel variants of PRKN and PINK1 genes in Vietnamese patients with early-onset Parkinson’s disease. Ton ND, Thuan ND, Thuong MTH, Ngoc TTB, Nhung VP, Hoa NTT, Nam NH, Dung HT, Son ND, Ba NV, Bac ND, Tai TN, Dung LTK, Hung NT, Duong NT, Ha NH, Hai NV. Mol Genet Genomic Med. 2020;8(10):e1463.
  • Microglia, inflammation and gut microbiota responses in a progressive monkey model of Parkinson’s disease: A case series. Joers V, Masilamoni G, Kempf D, Weiss AR, Rotterman TM, Murray B, Yalcin-Cakmakli G, Voll RJ, Goodman MM, Howell L, Bachevalier J, Green SJ, Naqib A, Shaikh M, Engen PA, Keshavarzian A, Barnum CJ, Nye JA, Smith Y, Tansey MG. Neurobiol Dis. 2020;144:105027.
  • Common diseases alter the physiological age-related blood microRNA profile. Fehlmann T, Lehallier B, Schaum N, Hahn O, Kahraman M, Li Y, Grammes N, Geffers L, Backes C, Balling R, Kern F, Kruger R, Lammert F, Ludwig N, Meder B, Fromm B, Maetzler W, Berg D, Brockmann K, Deuschle C, von Thaler AK, Eschweiler GW, Milman S, Barziliai N, Reichert M, Wyss-Coray T, Meese E, Keller A. Nat Commun. 2020;11(1):5958.
  • Dream enactment behavior: review for the clinician. Baltzan M, Yao C, Rizzo D, Postuma R. J Clin Sleep Med. 2020;16(11):1949-69.
  • Comparing GPS-Based Community Mobility Measures with Self-report Assessments in Older Adults with Parkinson’s Disease. Zhu L, Duval C, Boissy P, Montero-Odasso M, Zou G, Jog M, Speechley M. J Gerontol A Biol Sci Med Sci. 2020;75(12):2361-70.
  • Mitochondria interaction networks show altered topological patterns in Parkinson’s disease. Zanin M, Santos BFR, Antony PMA, Berenguer-Escuder C, Larsen SB, Hanss Z, Barbuti PA, Baumuratov AS, Grossmann D, Capelle CM, Weber J, Balling R, Ollert M, Kruger R, Diederich NJ, He FQ. NPJ Syst Biol Appl. 2020;6(1):38.
  • Characterization of the intestinal microbiota during Citrobacter rodentium infection in a mouse model of infection-triggered Parkinson’s disease. Cannon T, Sinha A, Trudeau LE, Maurice CF, Gruenheid S. Gut Microbes. 2020;12(1):1-11.
  • Monoamine oxidase A inhibition with moclobemide enhances the anti-parkinsonian effect of L-DOPA in the MPTP-lesioned marmoset. Hamadjida A, Nuara SG, Kwan C, Frouni I, Bedard D, Gourdon JC, Huot P. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(11):2157-64.
  • Monoamine oxidase A inhibition as monotherapy reverses parkinsonism in the MPTP-lesioned marmoset. Hamadjida A, Nuara SG, Frouni I, Kwan C, Bedard D, Gourdon JC, Huot P. Naunyn Schmiedebergs Arch Pharmacol. 2020;393(11):2139-44.
  • Reply To: Cerebral Vasomotor Reactivity in Parkinson’s Disease: A Missing Link between Dysautonomia, White Matter Lesions, and Cognitive Decline? Dadar M, Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB, Collins DL. Mov Disord Clin Pract. 2020;7(8):996-8.
  • Beneficial effects of cysteamine in Thy1-alpha-Syn mice and induced pluripotent stem cells with a SNCA gene triplication. Siddu A, David LS, Lauinger N, Chen X, Saint-Pierre M, Alpaugh M, Durcan T, Cicchetti F. Neurobiol Dis. 2020;145:105042.
  • Levodopa partially rescues microglial numerical, morphological, and phagolysosomal alterations in a monkey model of Parkinson’s disease. Lecours C, St-Pierre MK, Picard K, Bordeleau M, Bourque M, Awogbindin IO, Benadjal A, Ibanez FG, Gagnon D, Cantin L, Parent M, Di Paolo T, Tremblay ME. Brain Behav Immun. 2020;90:81-96.
  • Effect of Antidepressants on Psychotic Symptoms in Parkinson Disease: A Review of Case Reports and Case Series. Sid-Otmane L, Huot P, Panisset M. Clin Neuropharmacol. 2020;43(3):61-5.
  • Orthonasal, but not Retronasal Olfaction Is Specifically Impaired in Parkinson’s Disease. Aubry-Lafontaine E, Tremblay C, Durand-Martel P, Dupre N, Frasnelli J. Chem Senses. 2020;45(5):401-6.
  • Impaired mitochondrial-endoplasmic reticulum interaction and mitophagy in Miro1-mutant neurons in Parkinson’s disease. Berenguer-Escuder C, Grossmann D, Antony P, Arena G, Wasner K, Massart F, Jarazo J, Walter J, Schwamborn JC, Grunewald A, Kruger R. Hum Mol Genet. 2020;29(8):1353-64.
  • Isradipine Versus Placebo in Early Parkinson Disease: A Randomized Trial. Parkinson Study Group S-PDIIII. Ann Intern Med. 2020;172(9):591-8.
  • Genetic variability and potential effects on clinical trial outcomes: perspectives in Parkinson’s disease. Leonard H, Blauwendraat C, Krohn L, Faghri F, Iwaki H, Ferguson G, Day-Williams AG, Stone DJ, Singleton AB, Nalls MA, Gan-Or Z, International Parkinson’s Disease Genomic C. J Med Genet. 2020;57(5):331-8.
  • Initiation of pharmacological therapy in Parkinson’s disease: when, why, and how. de Bie RMA, Clarke CE, Espay AJ, Fox SH, Lang AE. Lancet Neurol. 2020;19(5):452-61.
  • Missing heritability in Parkinson’s disease: the emerging role of non-coding genetic variation. Ohnmacht J, May P, Sinkkonen L, Kruger R. J Neural Transm (Vienna). 2020;127(5):729-48.
  • Lysosome and Inflammatory Defects in GBA1-Mutant Astrocytes Are Normalized by LRRK2 Inhibition. Sanyal A, DeAndrade MP, Novis HS, Lin S, Chang J, Lengacher N, Tomlinson JJ, Tansey MG, LaVoie MJ. Mov Disord. 2020;35(5):760-73.
  • Induced pluripotent stem cell line (LCSBi001-A) derived from a patient with Parkinson’s disease carrying the p.D620N mutation in VPS35. Larsen SB, Hanss Z, Cruciani G, Massart F, Barbuti PA, Mellick G, Kruger R. Stem Cell Res. 2020;45:101776.
  • Penetrance of Parkinson’s Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score. Iwaki H, Blauwendraat C, Makarious MB, Bandres-Ciga S, Leonard HL, Gibbs JR, Hernandez DG, Scholz SW, Faghri F, International Parkinson’s Disease Genomics C, Nalls MA, Singleton AB. Mov Disord. 2020;35(5):774-80.
  • The Role of the Subthalamic Nucleus in Inhibitory Control of Oculomotor Behavior in Parkinson’s Disease. Bakhtiari S, Altinkaya A, Pack CC, Sadikot AF. Sci Rep. 2020;10(1):5429.
  • Disease modification and biomarker development in Parkinson disease: Revision or reconstruction? Espay AJ, Kalia LV, Gan-Or Z, Williams-Gray CH, Bedard PL, Rowe SM, Morgante F, Fasano A, Stecher B, Kauffman MA, Farrer MJ, Coffey CS, Schwarzschild MA, Sherer T, Postuma RB, Strafella AP, Singleton AB, Barker RA, Kieburtz K, Olanow CW, Lozano A, Kordower JH, Cedarbaum JM, Brundin P, Standaert DG, Lang AE. Neurology. 2020;94(11):481-94.
  • A broader perspective needed in Canadian guideline for Parkinson disease. Sack J. CMAJ. 2020;192(11):E289.
  • Ondansetron, a highly selective 5-HT3 receptor antagonist, reduces L-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease. Kwan C, Frouni I, Bedard D, Hamadjida A, Huot P. Eur J Pharmacol. 2020;871:172914.
  • Clinical and genetic analysis of ATP13A2 in hereditary spastic paraplegia expands the phenotype. Estiar MA, Leveille E, Spiegelman D, Dupre N, Trempe JF, Rouleau GA, Gan-Or Z. Mol Genet Genomic Med. 2020;8(3):e1052.
  • No genetic evidence for involvement of alcohol dehydrogenase genes in risk for Parkinson’s disease. Kim JJ, Bandres-Ciga S, Blauwendraat C, International Parkinson’s Disease Genomics C, Gan-Or Z. Neurobiol Aging. 2020;87:140 e19- e22.
  • Are Strategies Favoring Pattern Matching a Viable Way to Improve Complexity Estimation Based on Sample Entropy? Porta A, Valencia JF, Cairo B, Bari V, De Maria B, Gelpi F, Barbic F, Furlan R. Entropy (Basel). 2020;22(7).
  • Parkinson’s disease-associated alterations of the gut microbiome predict disease-relevant changes in metabolic functions. Baldini F, Hertel J, Sandt E, Thinnes CC, Neuberger-Castillo L, Pavelka L, Betsou F, Kruger R, Thiele I, Consortium N-P. BMC Biol. 2020;18(1):62.
  • Author Correction: Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease. Pontone GM, Dissanayaka N, Apostolova L, Brown RG, Dobkin R, Dujardin K, Friedman JH, Leentjens AFG, Lenze EJ, Marsh L, Mari L, Monchi O, Richard IH, Schrag A, Strafella AP, Vernaleo B, Weintraub D, Mari Z. NPJ Parkinsons Dis. 2020;6(1):10.
  • Emerging drugs for the treatment of L-DOPA-induced dyskinesia: an update. AlShimemeri S, Fox SH, Visanji NP. Expert Opin Emerg Drugs. 2020;25(2):131-44.
  • The highly selective mGlu2 receptor positive allosteric modulator LY-487,379 alleviates l-DOPA-induced dyskinesia in the 6-OHDA-lesioned rat model of Parkinson’s disease. Hamadjida A, Sid-Otmane L, Kwan C, Frouni I, Nafade V, Bedard D, Gagnon D, Wallman MJ, Rouillard C, Parent A, Parent M, Huot P. Eur J Neurosci. 2020;51(12):2412-22.
  • Beneficial effect of 24-month bilateral subthalamic stimulation on quality of sleep in Parkinson’s disease. Dafsari HS, Ray-Chaudhuri K, Ashkan K, Sachse L, Mahlstedt P, Silverdale M, Rizos A, Strack M, Jost ST, Reker P, Samuel M, Visser-Vandewalle V, Evans J, Antonini A, Martinez-Martin P, Timmermann L, Europar tINMPDSG. J Neurol. 2020;267(6):1830-41.
  • Exercise and Sleep in Parkinson’s Disease. Postuma RB. Mov Disord. 2020;35(6):918-20.
  • Addressing knowledge gaps in Parkinson’s disease: a report on the Movement Disorder Society’s Centre-to-Centre initiative to improve Parkinson’s disease services in Lao People’s Democratic Republic. Phokaewvarangkul O, Vorachit S, Phoumindr A, Keosodsay S, Postuma RB, Meissner WG, Bhidayasiri R. BMC Med Educ. 2020;20(1):239.
  • From apathy to addiction: Insights from neurology and psychiatry. Kirschner M, Rabinowitz A, Singer N, Dagher A. Prog Neuropsychopharmacol Biol Psychiatry. 2020;101:109926.
  • Parkinsonian Symptoms, Not Dyskinesia, Negatively Affect Active Life Participation of Dyskinetic Patients with Parkinson’s Disease. Goubault E, Bogard S, Blanchet PJ, Bezard E, Vincent C, Martino D, Sarna J, Monchi O, Duval C. Tremor Other Hyperkinet Mov (N Y). 2020;10:20.
  • Mapping the hyper-direct circuitry of impulsivity. Dagher A. Brain. 2020;143(7):1973-4.
  • Defining the Neural Kinome: Strategies and Opportunities for Small Molecule Drug Discovery to Target Neurodegenerative Diseases. Krahn AI, Wells C, Drewry DH, Beitel LK, Durcan TM, Axtman AD. ACS Chem Neurosci. 2020;11(13):1871-86.
  • Chronic Neuroleptic-Induced Parkinsonism Examined With Positron Emission Tomography. Galoppin M, Berroir P, Soucy JP, Suzuki Y, Lavigne GJ, Gagnon JF, Montplaisir JY, Stip E, Blanchet PJ. Mov Disord. 2020;35(7):1189-98.
  • Immunotherapy for Parkinson’s disease: stay tuned. Stoessl AJ. Lancet Neurol. 2020;19(7):561-2.
  • Comprehensive assessment of PINK1 variants in Parkinson’s disease. Krohn L, Grenn FP, Makarious MB, Kim JJ, Bandres-Ciga S, Roosen DA, Gan-Or Z, Nalls MA, Singleton AB, Blauwendraat C, International Parkinson’s Disease Genomics C. Neurobiol Aging. 2020;91:168 e1- e5.
  • Combined mGlu2 orthosteric stimulation and positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the parkinsonian marmoset. Nuara SG, Hamadjida A, Kwan C, Bedard D, Frouni I, Gourdon JC, Huot P. J Neural Transm (Vienna). 2020;127(7):1023-9.
  • The mGlu2/3 antagonist LY-341,495 reverses the anti-dyskinetic and anti-psychotic effects of the mGlu2 activators LY-487,379 and LY-354,740 in the MPTP-lesioned marmoset. Nuara SG, Hamadjida A, Gourdon JC, Huot P. J Neural Transm (Vienna). 2020;127(7):1013-21.
  • Obstructive Sleep Apnea in Neurodegenerative Disorders: Current Evidence in Support of Benefit from Sleep Apnea Treatment. Lajoie AC, Lafontaine AL, Kimoff RJ, Kaminska M. J Clin Med. 2020;9(2).
  • Microglial Phenotypes and Their Relationship to the Cannabinoid System: Therapeutic Implications for Parkinson’s Disease. Kelly R, Joers V, Tansey MG, McKernan DP, Dowd E. Molecules. 2020;25(3).
  • Genetic modifiers of risk and age at onset in GBA associated Parkinson’s disease and Lewy body dementia. Blauwendraat C, Reed X, Krohn L, Heilbron K, Bandres-Ciga S, Tan M, Gibbs JR, Hernandez DG, Kumaran R, Langston R, Bonet-Ponce L, Alcalay RN, Hassin-Baer S, Greenbaum L, Iwaki H, Leonard HL, Grenn FP, Ruskey JA, Sabir M, Ahmed S, Makarious MB, Pihlstrom L, Toft M, van Hilten JJ, Marinus J, Schulte C, Brockmann K, Sharma M, Siitonen A, Majamaa K, Eerola-Rautio J, Tienari PJ, andMe Research T, Pantelyat A, Hillis AE, Dawson TM, Rosenthal LS, Albert MS, Resnick SM, Ferrucci L, Morris CM, Pletnikova O, Troncoso J, Grosset D, Lesage S, Corvol JC, Brice A, Noyce AJ, Masliah E, Wood N, Hardy J, Shulman LM, Jankovic J, Shulman JM, Heutink P, Gasser T, Cannon P, Scholz SW, Morris H, Cookson MR, Nalls MA, Gan-Or Z, Singleton AB. Brain. 2020;143(1):234-48.
  • The noradrenergic system is necessary for survival of vulnerable midbrain dopaminergic neurons: implications for development and Parkinson’s disease. Hassani OK, Rymar VV, Nguyen KQ, Huo L, Cloutier JF, Miller FD, Sadikot AF. Neurobiol Aging. 2020;85:22-37.
  • Genetic, Structural, and Functional Evidence Link TMEM175 to Synucleinopathies. Krohn L, Ozturk TN, Vanderperre B, Ouled Amar Bencheikh B, Ruskey JA, Laurent SB, Spiegelman D, Postuma RB, Arnulf I, Hu MTM, Dauvilliers Y, Hogl B, Stefani A, Monaca CC, Plazzi G, Antelmi E, Ferini-Strambi L, Heidbreder A, Rudakou U, Cochen De Cock V, Young P, Wolf P, Oliva P, Zhang XK, Greenbaum L, Liong C, Gagnon JF, Desautels A, Hassin-Baer S, Montplaisir JY, Dupre N, Rouleau GA, Fon EA, Trempe JF, Lamoureux G, Alcalay RN, Gan-Or Z. Ann Neurol. 2020;87(1):139-53.
  • Obstructive sleep apnea, CPAP therapy and Parkinson’s disease motor function: A longitudinal study. Meng L, Benedetti A, Lafontaine AL, Mery V, Robinson AR, Kimoff J, Gros P, Kaminska M. Parkinsonism Relat Disord. 2020;70:45-50.
  • Neuroprotection and immunomodulation of progesterone in the gut of a mouse model of Parkinson’s disease. Jarras H, Bourque M, Poirier AA, Morissette M, Coulombe K, Di Paolo T, Soulet D. J Neuroendocrinol. 2020;32(1):e12782.
  • Optical coherence tomography of patients with Parkinson’s disease and progressive supranuclear palsy. Alkabie S, Lange A, Manogaran P, Stoessl AJ, Costello F, Barton JJS. Clin Neurol Neurosurg. 2020;189:105635.
  • Hallucinations, Delusions and Impulse Control Disorders in Parkinson Disease. Lizarraga KJ, Fox SH, Strafella AP, Lang AE. Clin Geriatr Med. 2020;36(1):105-18.
  • The impact of traumatic brain injury on cognitive and neuropsychiatric symptoms of Parkinson’s disease. Joyce JM, Monchi O, Ismail Z, Kibreab M, Cheetham J, Kathol I, Sarna J, Martino D, Debert CT. Int Rev Psychiatry. 2020;32(1):46-60.
  • Analysis of common and rare VPS13C variants in late-onset Parkinson disease. Rudakou U, Ruskey JA, Krohn L, Laurent SB, Spiegelman D, Greenbaum L, Yahalom G, Desautels A, Montplaisir JY, Fahn S, Waters CH, Levy O, Kehoe CM, Narayan S, Dauvilliers Y, Dupre N, Hassin-Baer S, Alcalay RN, Rouleau GA, Fon EA, Gan-Or Z. Neurol Genet. 2020;6(1):385.
  • Human Dopaminergic Neurons Lacking PINK1 Exhibit Disrupted Dopamine Metabolism Related to Vitamin B6 Co-Factors. Bus C, Zizmare L, Feldkaemper M, Geisler S, Zarani M, Schaedler A, Klose F, Admard J, Mageean CJ, Arena G, Fallier-Becker P, Ugun-Klusek A, Maruszczak KK, Kapolou K, Schmid B, Rapaport D, Ueffing M, Casadei N, Kruger R, Gasser T, Vogt Weisenhorn DM, Kahle PJ, Trautwein C, Gloeckner CJ, Fitzgerald JC. iScience. 2020;23(12):101797.
  • Dopamine imaging in prodromal Parkinson disease trials: Ready for prime time? Postuma RB. Neurology. 2020;95(23):1029-30.
  • Glycopyrrolate Improves Disability From Sialorrhea in Parkinson’s Disease: A 12-Week Controlled Trial. Mestre TA, Freitas E, Basndwah A, Lopez MR, de Oliveira LM, Al-Shorafat DM, Zhang T, Lui JP, Grimes D, Fox SH. Mov Disord. 2020;35(12):2319-23.
  • Helicobacter pylori Eradication in Parkinson’s Disease: A Randomized Placebo-Controlled Trial. Tan AH, Lim SY, Mahadeva S, Loke MF, Tan JY, Ang BH, Chin KP, Mohammad Adnan AF, Ong SMC, Ibrahim AI, Zulkifli N, Lee JK, Lim WT, Teo YT, Kok YL, Ng TY, Tan AGS, Zulkifle IM, Ng CK, Ee SS, Arafin S, Mohamad Shukori K, Vadivelu JS, Marras C, Fox SH, Lang AE. Mov Disord. 2020;35(12):2250-60.
  • How specific are non-motor symptoms in the prodrome of Parkinson’s disease compared to other movement disorders? Moscovich M, Heinzel S, Postuma RB, Reilmann R, Klockgether T, Jacobi H, Hoglinger G, Berg D. Parkinsonism Relat Disord. 2020;81:213-8.
  • Monoamine oxidase A inhibition and Parkinson’s disease. Huot P. Neurodegener Dis Manag. 2020;10(6):335-7.
  • Open-label titration of apomorphine sublingual film in patients with Parkinson’s disease and “OFF” episodes. Hui JS, Fox SH, Neeson W, Bhargava P, Pappert E, Blum D, Navia B, Investigators CTHS. Parkinsonism Relat Disord. 2020;79:110-6.
  • GBA variants in REM sleep behavior disorder: A multicenter study. Krohn L, Ruskey JA, Rudakou U, Leveille E, Asayesh F, Hu MTM, Arnulf I, Dauvilliers Y, Hogl B, Stefani A, Monaca CC, Abril B, Plazzi G, Antelmi E, Ferini-Strambi L, Heidbreder A, Boeve BF, Espay AJ, De Cock VC, Mollenhauer B, Sixel-Doring F, Trenkwalder C, Sonka K, Kemlink D, Figorilli M, Puligheddu M, Dijkstra F, Viaene M, Oertel W, Toffoli M, Gigli GL, Valente M, Gagnon JF, Desautels A, Montplaisir JY, Postuma RB, Rouleau GA, Gan-Or Z. Neurology. 2020;95(8):e1008-e16.
  • Dopamine is associated with prioritization of reward-associated memories in Parkinson’s disease. Sharp ME, Duncan K, Foerde K, Shohamy D. Brain. 2020;143(8):2519-31.
  • Substantia Nigra Volumetry with 3-T MRI in De Novo and Advanced Parkinson Disease. Vitali P, Pan MI, Palesi F, Germani G, Faggioli A, Anzalone N, Francaviglia P, Minafra B, Zangaglia R, Pacchetti C, Gandini Wheeler-Kingshott CAM. Radiology. 2020;296(2):401-10.
  • Magnetic Resonance Imaging and Neurofilament Light in the Differentiation of Parkinsonism. Archer DB, Mitchell T, Burciu RG, Yang J, Nigro S, Quattrone A, Quattrone A, Jeromin A, McFarland NR, Okun MS, Vaillancourt DE. Mov Disord. 2020;35(8):1388-95.
  • Initiating pharmacotherapy in early Parkinson’s disease. Lang AE, de Bie RMA, Clarke CE, Espay AJ, Fox SH. Lancet Neurol. 2020;19(8):643-4.
  • GBA variation and susceptibility to multiple system atrophy. Wernick AI, Walton RL, Koga S, Soto-Beasley AI, Heckman MG, Gan-Or Z, Ren Y, Rademakers R, Uitti RJ, Wszolek ZK, Cheshire WP, Dickson DW, Ross OA. Parkinsonism Relat Disord. 2020;77:64-9.
  • White Matter Hyperintensities Mediate Impact of Dysautonomia on Cognition in Parkinson’s Disease. Dadar M, Fereshtehnejad SM, Zeighami Y, Dagher A, Postuma RB, Collins DL. Mov Disord Clin Pract. 2020;7(6):639-47.
  • Selective metabotropic glutamate receptor 2 positive allosteric modulation alleviates L-DOPA-induced psychosis-like behaviours and dyskinesia in the MPTP-lesioned marmoset. Sid-Otmane L, Hamadjida A, Nuara SG, Bedard D, Gaudette F, Gourdon JC, Michaud V, Beaudry F, Panisset M, Huot P. Eur J Pharmacol. 2020;873:172957.
  • Linking mitochondria to the immune response. Wallings RL, Herrick MK, Tansey MG. Elife. 2020;9.
  • Changing vergence function in persons with Parkinson’s disease and convergence insufficiency. Machan CM, Chriqui E, Law C, Norman B, Alhassan M, Almeida QJ, Kergoat H, Irving EL. Parkinsonism Relat Disord. 2020;73:41-3.
  • Fine-Mapping of SNCA in Rapid Eye Movement Sleep Behavior Disorder and Overt Synucleinopathies. Krohn L, Wu RYJ, Heilbron K, Ruskey JA, Laurent SB, Blauwendraat C, Alam A, Arnulf I, Hu MTM, Dauvilliers Y, Hogl B, Toft M, Bjornara KA, Stefani A, Holzknecht E, Monaca CC, Abril B, Plazzi G, Antelmi E, Ferini-Strambi L, Young P, Heidbreder A, Cochen De Cock V, Mollenhauer B, Sixel-Doring F, Trenkwalder C, Sonka K, Kemlink D, Figorilli M, Puligheddu M, Dijkstra F, Viaene M, Oertel W, Toffoli M, Gigli GL, Valente M, Gagnon JF, Nalls MA, Singleton AB, andMe Research T, Desautels A, Montplaisir JY, Cannon P, Ross OA, Boeve BF, Dupre N, Fon EA, Postuma RB, Pihlstrom L, Rouleau GA, Gan-Or Z. Ann Neurol. 2020;87(4):584-98.
  • Decreased Penetrance of Parkinson’s Disease in Elderly Carriers of Glucocerebrosidase Gene L444P/R Mutations: A Community-Based 10-Year Longitudinal Study. Ji S, Wang C, Qiao H, Gu Z, Gan-Or Z, Fon EA, Chan P. Mov Disord. 2020;35(4):672-8.
  • Autophagy lysosomal pathway dysfunction in Parkinson’s disease; evidence from human genetics. Senkevich K, Gan-Or Z. Parkinsonism Relat Disord. 2020;73:60-71.
  • Theta-Burst Stimulation for Cognitive Enhancement in Parkinson’s Disease With Mild Cognitive Impairment: A Randomized, Double-Blind, Sham-Controlled Trial. Lang S, Gan LS, Yoon EJ, Hanganu A, Kibreab M, Cheetham J, Hammer T, Kathol I, Sarna J, Martino D, Monchi O. Front Neurol. 2020;11:584374.
  • GDNF and Parkinson’s Disease: Where Next? A Summary from a Recent Workshop. Barker RA, Bjorklund A, Gash DM, Whone A, Van Laar A, Kordower JH, Bankiewicz K, Kieburtz K, Saarma M, Booms S, Huttunen HJ, Kells AP, Fiandaca MS, Stoessl AJ, Eidelberg D, Federoff H, Voutilainen MH, Dexter DT, Eberling J, Brundin P, Isaacs L, Mursaleen L, Bresolin E, Carroll C, Coles A, Fiske B, Matthews H, Lungu C, Wyse RK, Stott S, Lang AE. J Parkinsons Dis. 2020;10(3):875-91.
  • Validation of an Individualized Measure of Quality of Life, Patient Generated Index, for Use with People with Parkinson’s Disease. Kuspinar A, Mate KKV, Lafontaine AL, Mayo N. Neurol Res Int. 2020;2020:6916135.
  • Prodromal PD: A new nosological entity. Schaeffer E, Postuma RB, Berg D. Prog Brain Res. 2020;252:331-56.
  • Age at Onset of Parkinson’s Disease Among Ashkenazi Jewish Patients: Contribution of Environmental Factors, LRRK2 p.G2019S and GBA p.N370S Mutations. Yahalom G, Rigbi A, Israeli-Korn S, Krohn L, Rudakou U, Ruskey JA, Benshimol L, Tsafnat T, Gan-Or Z, Hassin-Baer S, Greenbaum L. J Parkinsons Dis. 2020;10(3):1123-32.
  • Value of Clinical Signs in Identifying Patients with Scans without Evidence of Dopaminergic Deficit (SWEDD). Suwijn SR, Samim H, Eggers C, Espay AJ, Fox S, Lang AE, Samuel M, Silverdale M, Verschuur CVM, Dijk JM, Verberne HJ, Booij J, de Bie RMA. J Parkinsons Dis. 2020;10(4):1561-9.
  • LRRK2 at the Interface Between Peripheral and Central Immune Function in Parkinson’s. Wallings RL, Herrick MK, Tansey MG. Front Neurosci. 2020;14:443.
  • Olfactory bulb surroundings can help to distinguish Parkinson’s disease from non-parkinsonian olfactory dysfunction. Tremblay C, Mei J, Frasnelli J. Neuroimage Clin. 2020;28:102457.
  • Parkinson’s Disease Affects Functional Connectivity within the Olfactory-Trigeminal Network. Tremblay C, Iravani B, Aubry Lafontaine E, Steffener J, Fischmeister FPS, Lundstrom JN, Frasnelli J. J Parkinsons Dis. 2020;10(4):1587-600.
  • Association Between BDNF Val66Met Polymorphism and Mild Behavioral Impairment in Patients With Parkinson’s Disease. Ramezani M, Ruskey JA, Martens K, Kibreab M, Javer Z, Kathol I, Hammer T, Cheetham J, Leveille E, Martino D, Sarna JR, Gan-Or Z, Pfeffer G, Ismail Z, Monchi O. Front Neurol. 2020;11:587992.
  • Cerebellar Contribution to Motor and Non-motor Functions in Parkinson’s Disease: A Meta-Analysis of fMRI Findings. Solstrand Dahlberg L, Lungu O, Doyon J. Front Neurol. 2020;11:127.
  • Interaction of Alpha-Synuclein With Lipids: Mitochondrial Cardiolipin as a Critical Player in the Pathogenesis of Parkinson’s Disease. Gilmozzi V, Gentile G, Castelo Rueda MP, Hicks AA, Pramstaller PP, Zanon A, Levesque M, Pichler I. Front Neurosci. 2020;14:578993.
  • Predicting severity and prognosis in Parkinson’s disease from brain microstructure and connectivity. Abbasi N, Fereshtehnejad SM, Zeighami Y, Larcher KM, Postuma RB, Dagher A. Neuroimage Clin. 2020;25:102111.
  • Molecular Signatures of Neuroinflammation Induced by alphaSynuclein Aggregates in Microglial Cells. Sarkar S, Dammer EB, Malovic E, Olsen AL, Raza SA, Gao T, Xiao H, Oliver DL, Duong D, Joers V, Seyfried N, Huang M, Kukar T, Tansey MG, Kanthasamy AG, Rangaraju S. Front Immunol. 2020;11:33.
  • Genetic Architecture of Parkinson’s Disease in the Indian Population: Harnessing Genetic Diversity to Address Critical Gaps in Parkinson’s Disease Research. Rajan R, Divya KP, Kandadai RM, Yadav R, Satagopam VP, Madhusoodanan UK, Agarwal P, Kumar N, Ferreira T, Kumar H, Sreeram Prasad AV, Shetty K, Mehta S, Desai S, Kumar S, Prashanth LK, Bhatt M, Wadia P, Ramalingam S, Wali GM, Pandey S, Bartusch F, Hannussek M, Kruger J, Kumar-Sreelatha A, Grover S, Lichtner P, Sturm M, Roeper J, Busskamp V, Chandak GR, Schwamborn J, Seth P, Gasser T, Riess O, Goyal V, Pal PK, Borgohain R, Kruger R, Kishore A, Sharma M, Lux GC. Front Neurol. 2020;11:524.
  • Detecting the Cognitive Prodrome of Dementia in Parkinson’s Disease. De Roy J, Postuma RB, Brillon-Corbeil M, Montplaisir J, Genier Marchand D, Escudier F, Panisset M, Chouinard S, Gagnon JF. J Parkinsons Dis. 2020;10(3):1033-46.
  • Recommendations for the Organization of Multidisciplinary Clinical Care Teams in Parkinson’s Disease. Radder DLM, Nonnekes J, van Nimwegen M, Eggers C, Abbruzzese G, Alves G, Browner N, Chaudhuri KR, Ebersbach G, Ferreira JJ, Fleisher JE, Fletcher P, Frazzitta G, Giladi N, Guttman M, Iansek R, Khandhar S, Klucken J, Lafontaine AL, Marras C, Nutt J, Okun MS, Parashos SA, Munneke M, Bloem BR. J Parkinsons Dis. 2020;10(3):1087-98.
  • Novel data-driven, equation-free method captures spatio-temporal patterns of neurodegeneration in Parkinson’s disease: Application of dynamic mode decomposition to PET. Fu JF, Klyuzhin IS, McKeown MJ, Stoessl AJ, Sossi V. Neuroimage Clin. 2020;25:102150.
  • Erratum: Author Correction: Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease. Pontone GM, Dissanayaka N, Apostolova L, Brown RG, Dobkin R, Dujardin K, Friedman JH, Leentjens AFG, Lenze EJ, Marsh L, Mari L, Monchi O, Richard IH, Schrag A, Strafella AP, Vernaleo B, Weintraub D, Mari Z. NPJ Parkinsons Dis. 2020;6:10.
  • The Quebec Parkinson Network: A Researcher-Patient Matching Platform and Multimodal Biorepository. Gan-Or Z, Rao T, Leveille E, Degroot C, Chouinard S, Cicchetti F, Dagher A, Das S, Desautels A, Drouin-Ouellet J, Durcan T, Gagnon JF, Genge A, Karamchandani J, Lafontaine AL, Sun SLW, Langlois M, Levesque M, Melmed C, Panisset M, Parent M, Poline JB, Postuma RB, Pourcher E, Rouleau GA, Sharp M, Monchi O, Dupre N, Fon EA. J Parkinsons Dis. 2020;10(1):301-13.
  • Sphingosine-1-Phosphate Receptors Modulators Decrease Signs of Neuroinflammation and Prevent Parkinson’s Disease Symptoms in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine Mouse Model. Pepin E, Jalinier T, Lemieux GL, Massicotte G, Cyr M. Front Pharmacol. 2020;11:77.
  • The Emerging Role of RHOT1/Miro1 in the Pathogenesis of Parkinson’s Disease. Grossmann D, Berenguer-Escuder C, Chemla A, Arena G, Kruger R. Front Neurol. 2020;11:587.
  • Bidirectional Relation Between Parkinson’s Disease and Glioblastoma Multiforme. Mencke P, Hanss Z, Boussaad I, Sugier PE, Elbaz A, Kruger R. Front Neurol. 2020;11:898.
  • Toward Generating Subtype-Specific Mesencephalic Dopaminergic Neurons in vitro. Cardoso T, Levesque M. Front Cell Dev Biol. 2020;8:443.
  • Can We Predict the Motor Performance of Patients With Parkinson’s Disease Based on Their Symptomatology? Lebel K, Duval C, Goubault E, Bogard S, Blanchet PJ. Front Bioeng Biotechnol. 2020;8:189.
  • Mild behavioral impairment in Parkinson’s disease is associated with altered corticostriatal connectivity. Lang S, Yoon EJ, Kibreab M, Kathol I, Cheetham J, Hammer T, Sarna J, Ismail Z, Monchi O. Neuroimage Clin. 2020;26:102252.
  • Unmet Needs of People With Parkinson’s Disease and Their Caregivers During COVID-19-Related Confinement: An Explorative Secondary Data Analysis. Hanff AM, Pauly C, Pauly L, Schroder VE, Hansen M, Meyers GR, Kaysen A, Hansen L, Wauters F, Kruger R. Front Neurol. 2020;11:615172.

2019

  • Canadian guideline for Parkinson disease. Grimes D, Fitzpatrick M, Gordon J, Miyasaki J, Fon EA, Schlossmacher M, Suchowersky O, Rajput A, Lafontaine AL, Mestre T, Appel-Cresswell S, Kalia SK, Schoffer K, Zurowski M, Postuma RB, Udow S, Fox S, Barbeau P, Hutton B. CMAJ. 2019;191(36):E989-E1004.
  • The landscape of Parkin variants reveals pathogenic mechanisms and therapeutic targets in Parkinson’s disease. Yi W, MacDougall EJ, Tang MY, Krahn AI, Gan-Or Z, Trempe JF, Fon EA. Hum Mol Genet. 2019;28(17):2811-25.
  • Dopamine replacement remediates risk aversion in Parkinson’s disease in a value-independent manner. Cherkasova MV, Corrow JC, Taylor A, Yeung SC, Stubbs JL, McKeown MJ, Appel-Cresswell S, Stoessl AJ, Barton JJS. Parkinsonism Relat Disord. 2019;66:189-94.
  • Transcranial magnetic stimulation improves cognition over time in Parkinson’s disease. Trung J, Hanganu A, Jobert S, Degroot C, Mejia-Constain B, Kibreab M, Bruneau MA, Lafontaine AL, Strafella A, Monchi O. Parkinsonism Relat Disord. 2019;66:3-8.
  • Development and validation of the automated imaging differentiation in parkinsonism (AID-P): a multicentre machine learning study. Archer DB, Bricker JT, Chu WT, Burciu RG, McCracken JL, Lai S, Coombes SA, Fang R, Barmpoutis A, Corcos DM, Kurani AS, Mitchell T, Black ML, Herschel E, Simuni T, Parrish TB, Comella C, Xie T, Seppi K, Bohnen NI, Muller ML, Albin RL, Krismer F, Du G, Lewis MM, Huang X, Li H, Pasternak O, McFarland NR, Okun MS, Vaillancourt DE. Lancet Digit Health. 2019;1(5):e222-e31.
  • Development and Validation of the Automated Imaging Differentiation in Parkinsonism (AID-P): A Multi-Site Machine Learning Study. Archer DB, Bricker JT, Chu WT, Burciu RG, McCracken JL, Lai S, Coombes SA, Fang R, Barmpoutis A, Corcos DM, Kurani AS, Mitchell T, Black ML, Herschel E, Simuni T, Parrish TB, Comella C, Xie T, Seppi K, Bohnen NI, Muller M, Albin RL, Krismer F, Du G, Lewis MM, Huang X, Li H, Pasternak O, McFarland NR, Okun MS, Vaillancourt DE. Lancet Digit Health. 2019;1(5):e222-e31.
  • The impact of cognitive interventions on cognitive symptoms in idiopathic Parkinson’s disease: a systematic review. Couture M, Giguere-Rancourt A, Simard M. Neuropsychol Dev Cogn B Aging Neuropsychol Cogn. 2019;26(5):637-59.
  • Changes in Resting-State Functional Connectivity Related to Freezing of Gait in Parkinson’s Disease. Potvin-Desrochers A, Mitchell T, Gisiger T, Paquette C. Neuroscience. 2019;418:311-7.
  • Update of the MDS research criteria for prodromal Parkinson’s disease. Heinzel S, Berg D, Gasser T, Chen H, Yao C, Postuma RB, Disease MDSTFotDoPs. Mov Disord. 2019;34(10):1464-70.
  • 5-HT3 receptors in Parkinson’s disease psychosis: a forgotten target? Kwan C, Huot P. Neurodegener Dis Manag. 2019;9(5):251-3.
  • Neuronal vulnerability in Parkinson disease: Should the focus be on axons and synaptic terminals? Wong YC, Luk K, Purtell K, Burke Nanni S, Stoessl AJ, Trudeau LE, Yue Z, Krainc D, Oertel W, Obeso JA, Volpicelli-Daley LA. Mov Disord. 2019;34(10):1406-22.
  • Integrated Analyses of Microbiome and Longitudinal Metabolome Data Reveal Microbial-Host Interactions on Sulfur Metabolism in Parkinson’s Disease. Hertel J, Harms AC, Heinken A, Baldini F, Thinnes CC, Glaab E, Vasco DA, Pietzner M, Stewart ID, Wareham NJ, Langenberg C, Trenkwalder C, Kruger R, Hankemeier T, Fleming RMT, Mollenhauer B, Thiele I. Cell Rep. 2019;29(7):1767-77 e8.
  • Non-motor outcomes depend on location of neurostimulation in Parkinson’s disease. Petry-Schmelzer JN, Krause M, Dembek TA, Horn A, Evans J, Ashkan K, Rizos A, Silverdale M, Schumacher W, Sack C, Loehrer PA, Fink GR, Fonoff ET, Martinez-Martin P, Antonini A, Barbe MT, Visser-Vandewalle V, Ray-Chaudhuri K, Timmermann L, Dafsari HS, Europar, the IN-MPDSG. Brain. 2019;142(11):3592-604.
  • Activation of mGlu2/3 receptors, a novel therapeutic approach to alleviate dyskinesia and psychosis in experimental parkinsonism. Frouni I, Hamadjida A, Kwan C, Bedard D, Nafade V, Gaudette F, Nuara SG, Gourdon JC, Beaudry F, Huot P. Neuropharmacology. 2019;158:107725.
  • Local vulnerability and global connectivity jointly shape neurodegenerative disease propagation. Zheng YQ, Zhang Y, Yau Y, Zeighami Y, Larcher K, Misic B, Dagher A. PLoS Biol. 2019;17(11):e3000495.
  • Exposure to Pesticides and Welding Hastens the Age-at-Onset of Parkinson’s Disease. Gamache PL, Haj Salem I, Roux-Dubois N, Le Bouthillier J, Gan-Or Z, Dupre N. Can J Neurol Sci. 2019;46(6):711-6.
  • Intraoperative fiber optic guidance during chronic electrode implantation in deep brain stimulation neurosurgery: proof of concept in primates. DePaoli D, Goetz L, Gagnon D, Maranon G, Prud’homme M, Cantin L, Parent M, Cote DC. J Neurosurg. 2019;132(6):1810-9.
  • The toxin MPTP generates similar cognitive and locomotor deficits in hTau and tau knock-out mice. Gratuze M, Josset N, Petry FR, Pflieger M, Eyoum Jong L, Truchetti G, Poitras I, Julien J, Bezeau F, Morin F, Samadi P, Cicchetti F, Bretzner F, Planel E. Brain Res. 2019;1711:106-14.
  • Carriers of both GBA and LRRK2 mutations, compared to carriers of either, in Parkinson’s disease: Risk estimates and genotype-phenotype correlations. Yahalom G, Greenbaum L, Israeli-Korn S, Fay-Karmon T, Livneh V, Ruskey JA, Ronciere L, Alam A, Gan-Or Z, Hassin-Baer S. Parkinsonism Relat Disord. 2019;62:179-84.
  • Cerebral Metabolic Changes Related to Freezing of Gait in Parkinson Disease. Mitchell T, Potvin-Desrochers A, Lafontaine AL, Monchi O, Thiel A, Paquette C. J Nucl Med. 2019;60(5):671-6.
  • Prodromal Parkinson’s Disease: The Decade Past, the Decade to Come. Postuma RB, Berg D. Mov Disord. 2019;34(5):665-75.
  • Evaluating the content validity of generic preference-based measures for use in Parkinson’s disease. Kuspinar A, Mate K, Lafontaine AL, Mayo N. Parkinsonism Relat Disord. 2019;62:112-6.
  • Pridopidine, a clinic-ready compound, reduces 3,4-dihydroxyphenylalanine-induced dyskinesia in Parkinsonian macaques. Johnston TH, Geva M, Steiner L, Orbach A, Papapetropoulos S, Savola JM, Reynolds IJ, Ravenscroft P, Hill M, Fox SH, Brotchie JM, Laufer R, Hayden MR. Mov Disord. 2019;34(5):708-16.
  • Neuromelanin-sensitive MRI as a noninvasive proxy measure of dopamine function in the human brain. Cassidy CM, Zucca FA, Girgis RR, Baker SC, Weinstein JJ, Sharp ME, Bellei C, Valmadre A, Vanegas N, Kegeles LS, Brucato G, Kang UJ, Sulzer D, Zecca L, Abi-Dargham A, Horga G. Proc Natl Acad Sci U S A. 2019;116(11):5108-17.
  • Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson’s disease. Whone A, Luz M, Boca M, Woolley M, Mooney L, Dharia S, Broadfoot J, Cronin D, Schroers C, Barua NU, Longpre L, Barclay CL, Boiko C, Johnson GA, Fibiger HC, Harrison R, Lewis O, Pritchard G, Howell M, Irving C, Johnson D, Kinch S, Marshall C, Lawrence AD, Blinder S, Sossi V, Stoessl AJ, Skinner P, Mohr E, Gill SS. Brain. 2019;142(3):512-25.
  • Brain atrophy in Parkinson’s disease with polysomnography-confirmed REM sleep behavior disorder. Rahayel S, Gaubert M, Postuma RB, Montplaisir J, Carrier J, Monchi O, Remillard-Pelchat D, Bourgouin PA, Panisset M, Chouinard S, Joubert S, Gagnon JF. Sleep. 2019;42(6).
  • Stem cell therapy for neurological disorders: A focus on aging. Nguyen H, Zarriello S, Coats A, Nelson C, Kingsbury C, Gorsky A, Rajani M, Neal EG, Borlongan CV. Neurobiol Dis. 2019;126:85-104.
  • Parkinson’s disease age at onset genome-wide association study: Defining heritability, genetic loci, and alpha-synuclein mechanisms. Blauwendraat C, Heilbron K, Vallerga CL, Bandres-Ciga S, von Coelln R, Pihlstrom L, Simon-Sanchez J, Schulte C, Sharma M, Krohn L, Siitonen A, Iwaki H, Leonard H, Noyce AJ, Tan M, Gibbs JR, Hernandez DG, Scholz SW, Jankovic J, Shulman LM, Lesage S, Corvol JC, Brice A, van Hilten JJ, Marinus J, andMe Research T, Eerola-Rautio J, Tienari P, Majamaa K, Toft M, Grosset DG, Gasser T, Heutink P, Shulman JM, Wood N, Hardy J, Morris HR, Hinds DA, Gratten J, Visscher PM, Gan-Or Z, Nalls MA, Singleton AB, International Parkinson’s Disease Genomics C. Mov Disord. 2019;34(6):866-75.
  • Diagnostic delay in Parkinson’s disease caused by PRKN mutations. Ruiz-Lopez M, Freitas ME, Oliveira LM, Munhoz RP, Fox SH, Rohani M, Rogaeva E, Lang AE, Fasano A. Parkinsonism Relat Disord. 2019;63:217-20.
  • Mitochondrial antigen presentation: a mechanism linking Parkinson’s disease to autoimmunity. Fahmy AM, Boulais J, Desjardins M, Matheoud D. Curr Opin Immunol. 2019;58:31-7.
  • Network basis of the dysexecutive and posterior cortical cognitive profiles in Parkinson’s disease. Lang S, Hanganu A, Gan LS, Kibreab M, Auclair-Ouellet N, Alrazi T, Ramezani M, Cheetham J, Hammer T, Kathol I, Sarna J, Monchi O. Mov Disord. 2019;34(6):893-902.
  • Classic animal models of Parkinson’s disease: a historical perspective. Hamadjida A, Frouni I, Kwan C, Huot P. Behav Pharmacol. 2019;30(4):291-310.
  • Pleiotropic effects for Parkin and LRRK2 in leprosy type-1 reactions and Parkinson’s disease. Fava VM, Xu YZ, Lettre G, Van Thuc N, Orlova M, Thai VH, Tao S, Croteau N, Eldeeb MA, MacDougall EJ, Cambri G, Lahiri R, Adams L, Fon EA, Trempe JF, Cobat A, Alcais A, Abel L, Schurr E. Proc Natl Acad Sci U S A. 2019;116(31):15616-24.
  • Evolution of prodromal Parkinson’s disease and dementia with Lewy bodies: a prospective study. Fereshtehnejad SM, Yao C, Pelletier A, Montplaisir JY, Gagnon JF, Postuma RB. Brain. 2019;142(7):2051-67.
  • Gait and trunk kinematics during prolonged turning in Parkinson’s disease with freezing of gait. Mitchell T, Conradsson D, Paquette C. Parkinsonism Relat Disord. 2019;64:188-93.
  • Intestinal infection triggers Parkinson’s disease-like symptoms in Pink1(-/-) mice. Matheoud D, Cannon T, Voisin A, Penttinen AM, Ramet L, Fahmy AM, Ducrot C, Laplante A, Bourque MJ, Zhu L, Cayrol R, Le Campion A, McBride HM, Gruenheid S, Trudeau LE, Desjardins M. Nature. 2019;571(7766):565-9.
  • Infection triggers symptoms similar to those of Parkinson’s disease in mice lacking PINK1 protein. Herrick MK, Tansey MG. Nature. 2019;571(7766):481-2.
  • alpha-Synuclein in Parkinson’s disease: causal or bystander? Riederer P, Berg D, Casadei N, Cheng F, Classen J, Dresel C, Jost W, Kruger R, Muller T, Reichmann H, Riess O, Storch A, Strobel S, van Eimeren T, Volker HU, Winkler J, Winklhofer KF, Wullner U, Zunke F, Monoranu CM. J Neural Transm (Vienna). 2019;126(7):815-40.
  • Parkinson’s disease patients experiencing peak-dose dyskinesia redistribute involuntary movements throughout their body to improve motor control. Lebel K, Duval C, Goubault E, Bogard S, Blanchet PJ. Parkinsonism Relat Disord. 2019;64:312-4.
  • Algorithmic Complexity of EEG for Prognosis of Neurodegeneration in Idiopathic Rapid Eye Movement Behavior Disorder (RBD).Ruffini G, Ibanez D, Kroupi E, Gagnon JF, Montplaisir J, Postuma RB, Castellano M, Soria-Frisch A.  Ann Biomed Eng. 2019;47(1):282-96.
  • Increased yield of full GBA sequencing in Ashkenazi Jews with Parkinson’s disease. Ruskey JA, Greenbaum L, Ronciere L, Alam A, Spiegelman D, Liong C, Levy OA, Waters C, Fahn S, Marder KS, Chung W, Yahalom G, Israeli-Korn S, Livneh V, Fay-Karmon T, Alcalay RN, Hassin-Baer S, Gan-Or Z. Eur J Med Genet. 2019;62(1):65-9.
  • Immune system responses in Parkinson’s disease: Early and dynamic. Tansey MG, Romero-Ramos M. Eur J Neurosci. 2019;49(3):364-83.
  • LRRK2 regulation of immune-pathways and inflammatory disease. Wallings RL, Tansey MG. Biochem Soc Trans. 2019;47(6):1581-95.
  • Variants in Miro1 Cause Alterations of ER-Mitochondria Contact Sites in Fibroblasts from Parkinson’s Disease Patients. Berenguer-Escuder C, Grossmann D, Massart F, Antony P, Burbulla LF, Glaab E, Imhoff S, Trinh J, Seibler P, Grunewald A, Kruger R. J Clin Med. 2019;8(12).
  • Neuroprotection and immunomodulation in the gut of parkinsonian mice with a plasmalogen precursor. Nadeau J, Smith T, Lamontagne-Proulx J, Bourque M, Al Sweidi S, Jayasinghe D, Ritchie S, Di Paolo T, Soulet D. Brain Res. 2019;1725:146460.
  • Neurite orientation dispersion and density imaging (NODDI) and free-water imaging in Parkinsonism. Mitchell T, Archer DB, Chu WT, Coombes SA, Lai S, Wilkes BJ, McFarland NR, Okun MS, Black ML, Herschel E, Simuni T, Comella C, Xie T, Li H, Parrish TB, Kurani AS, Corcos DM, Vaillancourt DE. Hum Brain Mapp. 2019;40(17):5094-107.
  • ARSA variants in alpha-synucleinopathies. Makarious MB, Diez-Fairen M, Krohn L, Blauwendraat C, Bandres-Ciga S, Ding J, Pihlstrom L, Houlden H, Scholz SW, Gan-Or Z. Brain. 2019;142(12):e70.
  • Mutations in RHOT1 Disrupt Endoplasmic Reticulum-Mitochondria Contact Sites Interfering with Calcium Homeostasis and Mitochondrial Dynamics in Parkinson’s Disease. Grossmann D, Berenguer-Escuder C, Bellet ME, Scheibner D, Bohler J, Massart F, Rapaport D, Skupin A, Fouquier d’Herouel A, Sharma M, Ghelfi J, Rakovic A, Lichtner P, Antony P, Glaab E, May P, Dimmer KS, Fitzgerald JC, Grunewald A, Kruger R. Antioxid Redox Signal. 2019;31(16):1213-34.
  • Prodromal Marker Progression in Idiopathic Rapid Eye Movement Sleep Behavior Disorder: Sample Size for Clinical Trials. Alotaibi F, Pelletier A, Gagnon JF, Montplaisir JY, Postuma RB. Mov Disord. 2019;34(12):1914-9.
  • The Genetic Architecture of Parkinson Disease in Spain: Characterizing Population-Specific Risk, Differential Haplotype Structures, and Providing Etiologic Insight. Bandres-Ciga S, Ahmed S, Sabir MS, Blauwendraat C, Adarmes-Gomez AD, Bernal-Bernal I, Bonilla-Toribio M, Buiza-Rueda D, Carrillo F, Carrion-Claro M, Gomez-Garre P, Jesus S, Labrador-Espinosa MA, Macias D, Mendez-Del-Barrio C, Perinan-Tocino T, Tejera-Parrado C, Vargas-Gonzalez L, Diez-Fairen M, Alvarez I, Tartari JP, Buongiorno M, Aguilar M, Gorostidi A, Bergareche JA, Mondragon E, Vinagre-Aragon A, Croitoru I, Ruiz-Martinez J, Dols-Icardo O, Kulisevsky J, Marin-Lahoz J, Pagonabarraga J, Pascual-Sedano B, Ezquerra M, Camara A, Compta Y, Fernandez M, Fernandez-Santiago R, Munoz E, Tolosa E, Valldeoriola F, Gonzalez-Aramburu I, Sanchez Rodriguez A, Sierra M, Menendez-Gonzalez M, Blazquez M, Garcia C, Suarez-San Martin E, Garcia-Ruiz P, Martinez-Castrillo JC, Vela-Desojo L, Ruz C, Barrero FJ, Escamilla-Sevilla F, Minguez-Castellanos A, Cerdan D, Tabernero C, Gomez Heredia MJ, Perez Errazquin F, Romero-Acebal M, Feliz C, Lopez-Sendon JL, Mata M, Martinez Torres I, Kim JJ, Dalgard CL, American Genome C, Brooks J, Saez-Atienzar S, Gibbs JR, Jorda R, Botia JA, Bonet-Ponce L, Morrison KE, Clarke C, Tan M, Morris H, Edsall C, Hernandez D, Simon-Sanchez J, Nalls MA, Scholz SW, Jimenez-Escrig A, Duarte J, Vives F, Duran R, Hoenicka J, Alvarez V, Infante J, Marti MJ, Clarimon J, Lopez de Munain A, Pastor P, Mir P, Singleton A, International Parkinson Disease Genomics C. Mov Disord. 2019;34(12):1851-63.
  • Mechanisms of PINK1, ubiquitin and Parkin interactions in mitochondrial quality control and beyond. Bayne AN, Trempe JF. Cell Mol Life Sci. 2019;76(23):4589-611.
  • Identification of novel risk loci, causal insights, and heritable risk for Parkinson’s disease: a meta-analysis of genome-wide association studies. Nalls MA, Blauwendraat C, Vallerga CL, Heilbron K, Bandres-Ciga S, Chang D, Tan M, Kia DA, Noyce AJ, Xue A, Bras J, Young E, von Coelln R, Simon-Sanchez J, Schulte C, Sharma M, Krohn L, Pihlstrom L, Siitonen A, Iwaki H, Leonard H, Faghri F, Gibbs JR, Hernandez DG, Scholz SW, Botia JA, Martinez M, Corvol JC, Lesage S, Jankovic J, Shulman LM, Sutherland M, Tienari P, Majamaa K, Toft M, Andreassen OA, Bangale T, Brice A, Yang J, Gan-Or Z, Gasser T, Heutink P, Shulman JM, Wood NW, Hinds DA, Hardy JA, Morris HR, Gratten J, Visscher PM, Graham RR, Singleton AB, andMe Research T, System Genomics of Parkinson’s Disease C, International Parkinson’s Disease Genomics C. Lancet Neurol. 2019;18(12):1091-102.
  • Specific intranasal and central trigeminal electrophysiological responses in Parkinson’s disease. Tremblay C, Emrich R, Cavazzana A, Klingelhoefer L, Brandt MD, Hummel T, Haehner A, Frasnelli J. J Neurol. 2019;266(12):2942-51.
  • The Parkinson’s Disease Mendelian Randomization Research Portal. Noyce AJ, Bandres-Ciga S, Kim J, Heilbron K, Kia D, Hemani G, Xue A, Lawlor DA, Smith GD, Duran R, Gan-Or Z, Blauwendraat C, Gibbs JR, andMe Research Team IPsDGC, Hinds DA, Yang J, Visscher P, Cuzick J, Morris H, Hardy J, Wood NW, Nalls MA, Singleton AB. Mov Disord. 2019;34(12):1864-72.
  • Neuroimaging biomarkers for clinical trials in atypical parkinsonian disorders: Proposal for a Neuroimaging Biomarker Utility System. van Eimeren T, Antonini A, Berg D, Bohnen N, Ceravolo R, Drzezga A, Hoglinger GU, Higuchi M, Lehericy S, Lewis S, Monchi O, Nestor P, Ondrus M, Pavese N, Peralta MC, Piccini P, Pineda-Pardo JA, Rektorova I, Rodriguez-Oroz M, Rominger A, Seppi K, Stoessl AJ, Tessitore A, Thobois S, Kaasinen V, Wenning G, Siebner HR, Strafella AP, Rowe JB. Alzheimers Dement (Amst). 2019;11:301-9.
  • Antibody-based therapies for Huntington’s disease: current status and future directions. Denis HL, David LS, Cicchetti F. Neurobiol Dis. 2019;132:104569.
  • Exercise increases caudate dopamine release and ventral striatal activation in Parkinson’s disease. Sacheli MA, Neva JL, Lakhani B, Murray DK, Vafai N, Shahinfard E, English C, McCormick S, Dinelle K, Neilson N, McKenzie J, Schulzer M, McKenzie DC, Appel-Cresswell S, McKeown MJ, Boyd LA, Sossi V, Stoessl AJ. Mov Disord. 2019;34(12):1891-900.
  • Mild behavioral impairment is linked to worse cognition and brain atrophy in Parkinson disease. Yoon EJ, Ismail Z, Hanganu A, Kibreab M, Hammer T, Cheetham J, Kathol I, Sarna JR, Martino D, Furtado S, Monchi O. Neurology. 2019;93(8):e766-e77.
  • Increased vulnerability of nigral dopamine neurons after expansion of their axonal arborization size through D2 dopamine receptor conditional knockout. Giguere N, Delignat-Lavaud B, Herborg F, Voisin A, Li Y, Jacquemet V, Anand-Srivastava M, Gether U, Giros B, Trudeau LE. PLoS Genet. 2019;15(8):e1008352.
  • The clinical significance of lower limb tremors. Rajalingam R, Breen DP, Chen R, Fox S, Kalia LV, Munhoz RP, Slow E, Strafella AP, Lang AE, Fasano A. Parkinsonism Relat Disord. 2019;65:165-71.
  • Using global team science to identify genetic parkinson’s disease worldwide. Vollstedt EJ, Kasten M, Klein C, Group MGGPsDS. Ann Neurol. 2019;86(2):153-7.
  • The second generation mixed lineage kinase-3 (MLK3) inhibitor CLFB-1134 protects against neurotoxin-induced nigral dopaminergic neuron loss. Kline EM, Butkovich LM, Bradner JM, Chang J, Gelbard H, Goodfellow V, Caudle WM, Tansey MG. Exp Neurol. 2019;318:157-64.
  • Prodromal Parkinson disease: do we miss the signs? Postuma RB. Nat Rev Neurol. 2019;15(8):437-8.
  • Glucocerebrosidase mutations and phenoconversion of REM sleep behavior disorder to parkinsonism and dementia. Honeycutt L, Montplaisir JY, Gagnon JF, Ruskey J, Pelletier A, Gan-Or Z, Postuma RB. Parkinsonism Relat Disord. 2019;65:230-3.
  • A novel wireless brain stimulation device for long-term use in freely moving mice. Alpaugh M, Saint-Pierre M, Dubois M, Aube B, Arsenault D, Kriz J, Cicchetti A, Cicchetti F. Sci Rep. 2019;9(1):6444.
  • A clinical-anatomical signature of Parkinson’s disease identified with partial least squares and magnetic resonance imaging. Zeighami Y, Fereshtehnejad SM, Dadar M, Collins DL, Postuma RB, Misic B, Dagher A. Neuroimage. 2019;190:69-78.
  • The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson’s disease. Bandres-Ciga S, Saez-Atienzar S, Bonet-Ponce L, Billingsley K, Vitale D, Blauwendraat C, Gibbs JR, Pihlstrom L, Gan-Or Z, International Parkinson’s Disease Genomics C, Cookson MR, Nalls MA, Singleton AB. Mov Disord. 2019;34(4):460-8.
  • Prospective memory in idiopathic REM sleep behavior disorder with or without mild cognitive impairment: A preliminary study. Marcone S, Gagnon JF, Desjardins C, David AC, Postuma RB, Montplaisir J, Joubert S, Rouleau I. Clin Neuropsychol. 2019;33(3):571-93.
  • SMPD1 mutations, activity, and alpha-synuclein accumulation in Parkinson’s disease. Alcalay RN, Mallett V, Vanderperre B, Tavassoly O, Dauvilliers Y, Wu RYJ, Ruskey JA, Leblond CS, Ambalavanan A, Laurent SB, Spiegelman D, Dionne-Laporte A, Liong C, Levy OA, Fahn S, Waters C, Kuo SH, Chung WK, Ford B, Marder KS, Kang UJ, Hassin-Baer S, Greenbaum L, Trempe JF, Wolf P, Oliva P, Zhang XK, Clark LN, Langlois M, Dion PA, Fon EA, Dupre N, Rouleau GA, Gan-Or Z. Mov Disord. 2019;34(4):526-35.
  • Portrait of blood-derived extracellular vesicles in patients with Parkinson’s disease. Lamontagne-Proulx J, St-Amour I, Labib R, Pilon J, Denis HL, Cloutier N, Roux-Dalvai F, Vincent AT, Mason SL, Williams-Gray C, Duchez AC, Droit A, Lacroix S, Dupre N, Langlois M, Chouinard S, Panisset M, Barker RA, Boilard E, Cicchetti F. Neurobiol Dis. 2019;124:163-75.
  • Understanding the role of genetic variability in LRRK2 in Indian population. Kishore A, Ashok Kumar Sreelatha A, Sturm M, von-Zweydorf F, Pihlstrom L, Raimondi F, Russell R, Lichtner P, Banerjee M, Krishnan S, Rajan R, Puthenveedu DK, Chung SJ, International Parkinson’s Disease Genomics C, Comprehensive Unbiased Risk Factor Assessment for G, Environment in Parkinson’s D, Bauer P, Riess O, Gloeckner CJ, Kruger R, Gasser T, Sharma M. Mov Disord. 2019;34(4):496-505.
  • Malassezia and Parkinson’s Disease. Laurence M, Benito-Leon J, Calon F. Front Neurol. 2019;10:758.
  • Remnants of Cardinal Symptoms of Parkinson’s Disease, Not Dyskinesia, Are Problematic for Dyskinetic Patients Performing Activities of Daily Living. Goubault E, Nguyen HP, Bogard S, Blanchet PJ, Bezard E, Vincent C, Sarna J, Monchi O, Duval C. Front Neurol. 2019;10:256.
  • Moving beyond neurons: the role of cell type-specific gene regulation in Parkinson’s disease heritability. Reynolds RH, Botia J, Nalls MA, International Parkinson’s Disease Genomics C, System Genomics of Parkinson’s D, Hardy J, Gagliano Taliun SA, Ryten M. NPJ Parkinsons Dis. 2019;5:6.
  • Deep Learning With EEG Spectrograms in Rapid Eye Movement Behavior Disorder. Ruffini G, Ibanez D, Castellano M, Dubreuil-Vall L, Soria-Frisch A, Postuma R, Gagnon JF, Montplaisir J. Front Neurol. 2019;10:806.
  • A Proposed Roadmap for Parkinson’s Disease Proof of Concept Clinical Trials Investigating Compounds Targeting Alpha-Synuclein. Merchant KM, Cedarbaum JM, Brundin P, Dave KD, Eberling J, Espay AJ, Hutten SJ, Javidnia M, Luthman J, Maetzler W, Menalled L, Reimer AN, Stoessl AJ, Weiner DM, The Michael JFFASCPWG. J Parkinsons Dis. 2019;9(1):31-61.
  • Rheumatoid Meningitis Presenting With Acute Parkinsonism and Protracted Non-convulsive Seizures: An Unusual Case Presentation and Review of Treatment Strategies. Pellerin D, Wodkowski M, Guiot MC, AlDhukair H, Blotsky A, Karamchandani J, Vinet E, Lafontaine AL, Lubarsky S. Front Neurol. 2019;10:163.
  • Joint pattern analysis applied to PET DAT and VMAT2 imaging reveals new insights into Parkinson’s disease induced presynaptic alterations. Fu JF, Klyuzhin I, McKenzie J, Neilson N, Shahinfard E, Dinelle K, McKeown MJ, Stoessl AJ, Sossi V. Neuroimage Clin. 2019;23:101856.
  • Multilingual Validation of the First French Version of Munich Dysphagia Test-Parkinson’s Disease (MDT-PD) in the Luxembourg Parkinson’s Study. Simons JA, Vaillant M, Hipp G, Pavelka L, Stute L, Pauly C, Kruger R. Front Neurol. 2019;10:1180.
  • Extended Treatment with Glial Cell Line-Derived Neurotrophic Factor in Parkinson’s Disease. Whone AL, Boca M, Luz M, Woolley M, Mooney L, Dharia S, Broadfoot J, Cronin D, Schroers C, Barua NU, Longpre L, Barclay CL, Boiko C, Johnson GA, Fibiger HC, Harrison R, Lewis O, Pritchard G, Howell M, Irving C, Johnson D, Kinch S, Marshall C, Lawrence AD, Blinder S, Sossi V, Stoessl AJ, Skinner P, Mohr E, Gill SS. J Parkinsons Dis. 2019;9(2):301-13.
  • One Step Into the Future: New iPSC Tools to Advance Research in Parkinson’s Disease and Neurological Disorders. Mohamed NV, Larroquette F, Beitel LK, Fon EA, Durcan TM. J Parkinsons Dis. 2019;9(2):265-81.
  • Report from a multidisciplinary meeting on anxiety as a non-motor manifestation of Parkinson’s disease. Pontone GM, Dissanayka N, Apostolova L, Brown RG, Dobkin R, Dujardin K, Friedman JH, Leentjens AFG, Lenze EJ, Marsh L, Mari L, Monchi O, Richard IH, Schrag A, Strafella AP, Vernaleo B, Weintraub D, Mari Z. NPJ Parkinsons Dis. 2019;5:30.
  • Diabetes, a Contemporary Risk for Parkinson’s Disease: Epidemiological and Cellular Evidences. Sergi D, Renaud J, Simola N, Martinoli MG. Front Aging Neurosci. 2019;11:302.
  • Assessment of a prognostic MRI biomarker in early de novo Parkinson’s disease. Zeighami Y, Fereshtehnejad SM, Dadar M, Collins DL, Postuma RB, Dagher A. Neuroimage Clin. 2019;24:101986.
  • Association Between Social Cognition Changes and Resting State Functional Connectivity in Frontotemporal Dementia, Alzheimer’s Disease, Parkinson’s Disease, and Healthy Controls. Multani N, Taghdiri F, Anor CJ, Varriano B, Misquitta K, Tang-Wai DF, Keren R, Fox S, Lang AE, Vijverman AC, Marras C, Tartaglia MC. Front Neurosci. 2019;13:1259.
  • Responsiveness to Change of the Montreal Cognitive Assessment, Mini-Mental State Examination, and SCOPA-Cog in Non-Demented Patients with Parkinson’s Disease. Faust-Socher A, Duff-Canning S, Grabovsky A, Armstrong MJ, Rothberg B, Eslinger PJ, Meaney CA, Schneider RB, Tang-Wai DF, Fox SH, Zadikoff C, Kennedy N, Chou KL, Persad C, Litvan I, Mast BT, Gerstenecker AT, Weintraub S, Reginold W, Marras C. Dement Geriatr Cogn Disord. 2019;47(4-6):187-97.
  • Quality Control Strategy for CRISPR-Cas9-Based Gene Editing Complicated by a Pseudogene. Hanss Z, Boussaad I, Jarazo J, Schwamborn JC, Kruger R. Front Genet. 2019;10:1297.
  • Alpha-Synuclein Proximity Ligation Assay (AS-PLA) in Brain Sections to Probe for Alpha-Synuclein Oligomers. Roberts RF, Bengoa-Vergniory N, Alegre-Abarrategui J. Methods Mol Biol. 2019;1948:69-76.
  • Why Is Aging a Risk Factor for Cognitive Impairment in Parkinson’s Disease?-A Resting State fMRI Study. Nagano-Saito A, Bellec P, Hanganu A, Jobert S, Mejia-Constain B, Degroot C, Lafontaine AL, Lissemore JI, Smart K, Benkelfat C, Monchi O. Front Neurol. 2019;10:267.
  • Impaired Fine Motor Function of the Asymptomatic Hand in Unilateral Parkinson’s Disease. Dan X, Liu J, Doyon J, Zhou Y, Ma J, Chan P. Front Aging Neurosci. 2019;11:266.
  • Anodal tDCS modulates cortical activity and synchronization in Parkinson’s disease depending on motor processing. Schoellmann A, Scholten M, Wasserka B, Govindan RB, Kruger R, Gharabaghi A, Plewnia C, Weiss D. Neuroimage Clin. 2019;22:101689.
  • Abnormal Muscle Activity and Variability Before, During, and After the Occurrence of Freezing in Parkinson’s Disease. Cantu H, Nantel J, Millan M, Paquette C, Cote JN. Front Neurol. 2019;10:951.
  • Mitochondria function associated genes contribute to Parkinson’s Disease risk and later age at onset. Billingsley KJ, Barbosa IA, Bandres-Ciga S, Quinn JP, Bubb VJ, Deshpande C, Botia JA, Reynolds RH, Zhang D, Simpson MA, Blauwendraat C, Gan-Or Z, Gibbs JR, Nalls MA, Singleton A, International Parkinson’s Disease Genomics C, Ryten M, Koks S. NPJ Parkinsons Dis. 2019;5:8.
  • Biomarkers of Parkinson’s disease: Striatal sub-regional structural morphometry and diffusion MRI. Khan AR, Hiebert NM, Vo A, Wang BT, Owen AM, Seergobin KN, MacDonald PA. Neuroimage Clin. 2019;21:101597.